SOURCE: Goldman Small Cap Research, Inc.

October 23, 2013 10:38 ET

Nuvilex, Inc.: Anatomy of a Biotech

BALTIMORE, MD--(Marketwired - Oct 23, 2013) - In a newly released article, Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that a series of upcoming milestone news events appear to be catalysts that should move the shares of Nuvilex, Inc. (OTCQB: NVLX) substantially higher, prior to the seasonal biotech surge.

Due to the nature of the research and development process, biotechnology stocks typically do not generate a lot of news flow regarding milestone events. In fact, due to a plethora of key conferences in high-profile treatment categories such as cancer and diabetes, it seems as if many biotech stocks have news front-end loaded in the first half of the year, which helps drive valuations and share prices. In the absence of news or the achievement of milestone events, these stocks tend to decline throughout the second half of the year, prior to beginning the cycle all over again in the late fourth quarter of the year.

Nuvilex has only incrementally participated in this biotech stock decline and before year-end, it is anticipated that the Company will not only provide a progress report on its live-cell encapsulation-based therapy to treat pancreatic cancer but also should close on the acquisition of the rights to use that same technology platform for the development of a diabetes therapy. Such an event would dramatically boost the Company's valuation given the huge, untapped market opportunity that lies ahead for Nuvilex. Interestingly, during this time of year, a number of early - mid stage biotechs engage in dilutive financings that can also serve as a drag on biotech shares. As evidenced by the largely non-dilutive fundraising event by Nuvilex earlier this year for the oncology rights, investors do not have to worry about management engaging in these types of financings to further its R&D objectives, which is a major plus.

Looking ahead, progress on the GMP (Good Manufacturing Practices) facility in which the cell encapsulation for its pancreatic cancer treatment will be done, a requirement for all Phase 3 clinical trials, and the cell cloning and cell storage initiatives will likely catch the attention of investors and biotech watchers alike later this year, again boosting these shares. In the near term, the pending 3Q13 financial report from Celgene which is due later this week will place further attention on the pancreatic cancer treatment sector, and by association, Nuvilex. 

Clearly, Nuvilex is not built like typical biotechs. And that is a good thing. 

This press release contains excerpts of our most recently published article on Nuvilex. To view all of our sponsored Nuvilex reports, updates, articles, disclosures and disclaimers, or to download the article in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer, diabetes and other diseases based on the live, therapeutically valuable, encapsulated cells platform. The Company is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating oncology applications of medical marijuana. For more information visit:

Contact Information